Evidence map›Paper›PMID 35527225›Full record

ArticleVirologica Sinica2022

An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.

Ningning Ge, Jin Sun, Zhihua Liu, Jiayi Shu, Huimin Yan, Zhihua Kou, Yu Wei, Xia Jin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virologica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Rational design of lipid nanoparticles for enabling gene therapies.Molecular therapy. Methods & clinical development · 2025
    Review
  7. Review
  8. Article
  9. Research progress of mosquito-borne virus mRNA vaccines.Molecular therapy. Methods & clinical development · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ningning GeCAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Jin SunCAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
Zhihua LiuShanghai Public Health Clinical Center, Fudan University, Shanghai 200540, China.
Jiayi ShuShanghai Public Health Clinical Center, Fudan University, Shanghai 200540, China.
Huimin YanShanghai Public Health Clinical Center, Fudan University, Shanghai 200540, China; Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
Zhihua KouShanghai Public Health Clinical Center, Fudan University, Shanghai 200540, China. Electronic address: kouzhihua@shphc.org.cn.
Yu WeiCAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: yuwei@ips.ac.cn.
Xia JinShanghai Public Health Clinical Center, Fudan University, Shanghai 200540, China. Electronic address: jinxia@serum-china.com.cn.
Shanghai Public Health Clinical Center · CNInstitut Pasteur of Shanghai · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arthropod-borne chikungunya virus (CHIKV) infection can cause a debilitating arthritic disease in human. However, there are no specific antiviral drugs and effective licensed vaccines against CHIKV available for clinical use. Here, we developed an mRNA-lipid nanoparticle (mRNA-LNP) vaccine expressing CHIKV E2-E1 antigen, and compared its immunogenicity with soluble recombinant protein sE2-E1 antigen expressed in S2 cells. For comparison, we first showed that recombinant protein antigens mixed with aluminum adjuvant elicit strong antigen-specific humoral immune response and a moderate cellular immune response in C57BL/6 mice. Moreover, sE2-E1 vaccine stimulated 12-23 folds more neutralizing antibodies than sE1 vaccine and sE2 vaccine. Significantly, when E2-E1 gene was delivered by an mRNA-LNP vaccine, not only the better magnitude of neutralizing antibody responses was induced, but also greater cellular immune responses were generated, especially for CD8

Indexed as

Antibody FormationChikungunya FeverImmunity, CellularmRNA VaccinesViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesChikungunya virusLiposomesMiceMice, Inbred C57BLNanoparticlesVaccines, SyntheticViral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralLipid NanoparticlesLiposomesmRNA VaccinesVaccines, SyntheticViral Envelope ProteinsViral VaccinesChikungunya virus (CHIKV)Cytotoxic T-lymphocytes (CTL)mRNA vaccineNeutralizing antibody

Identifiers

PMID35527225
PMCPMC9170975
OpenAlexW4210638775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.